Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) EBT Margin (2020 - 2025)

Historic EBT Margin for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q3 2025 value amounting to 1.99%.

  • Mirum Pharmaceuticals' EBT Margin rose 173500.0% to 1.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.65%, marking a year-over-year increase of 232600.0%. This contributed to the annual value of 25.8% for FY2024, which is 613500.0% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported EBT Margin of 1.99% as of Q3 2025, which was up 173500.0% from 4.27% recorded in Q2 2025.
  • Mirum Pharmaceuticals' EBT Margin's 5-year high stood at 1825.75% during Q4 2021, with a 5-year trough of 941.98% in Q3 2021.
  • Its 5-year average for EBT Margin is 45.71%, with a median of 49.92% in 2023.
  • Over the last 5 years, Mirum Pharmaceuticals' EBT Margin had its largest YoY gain of 7519200bps in 2022, and its largest YoY loss of -19558000bps in 2022.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' EBT Margin stood at 1825.75% in 2021, then tumbled by -107bps to 130.05% in 2022, then surged by 61bps to 50.94% in 2023, then soared by 52bps to 24.51% in 2024, then soared by 108bps to 1.99% in 2025.
  • Its EBT Margin stands at 1.99% for Q3 2025, versus 4.27% for Q2 2025 and 12.23% for Q1 2025.